5.01

2.24% 0.11

Atara Biotherapeutics Inc (ATRA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ATRA Giù? Forum Previsione

Precedente Chiudi:

$4.90

Aprire:

$4.94

Volume 24 ore:

26,580

Relative Volume:

0.13

Capitalizzazione di mercato:

$40.97M

Reddito:

$120.77M

Utile/perdita netta:

$32.69M

Rapporto P/E:

1.7189

EPS:

2.9146

Flusso di cassa netto:

$-50.94M

1 W Prestazione:

-4.93%

1M Prestazione:

+0.40%

6M Prestazione:

-65.42%

1 anno Prestazione:

-34.08%

Intervallo 1D:

$4.8005

$5.1117

Intervallo di 1 settimana:

$4.8005

$5.30

Portata 52W:

$3.92

$19.14

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Nome

Atara Biotherapeutics Inc

Settore

Healthcare (1108)

Industria

Biotechnology (619)

Telefono

805-623-4211

Indirizzo

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Dipendente

Cinguettio

@Atarabio

Prossima data di guadagno

2026-05-21

Ultimi documenti SEC

ATRA's Discussions on Twitter

Compare ATRA vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ATRA Atara Biotherapeutics Inc	5.01	40.97M	120.77M	32.69M	-50.94M	2.9146
VRTX Vertex Pharmaceuticals Inc	430.29	109.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	751.57	79.46B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	780.25	48.52B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	305.54	40.77B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	300.80	33.39B	5.36B	287.73M	924.18M	2.5229

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-13	Downgrade	Canaccord Genuity	Buy → Hold
2023-11-09	Downgrade	Evercore ISI	Outperform → In-line
2023-11-09	Downgrade	H.C. Wainwright	Buy → Neutral
2023-11-09	Downgrade	Mizuho	Buy → Neutral
2022-07-20	Downgrade	Citigroup	Neutral → Sell
2022-07-13	Downgrade	JP Morgan	Overweight → Neutral
2022-07-13	Downgrade	Stifel	Buy → Hold
2022-05-10	Downgrade	Citigroup	Buy → Neutral
2021-05-13	Aggiornamento	JP Morgan	Neutral → Overweight
2020-12-09	Downgrade	Citigroup	Buy → Neutral
2020-12-08	Reiterato	H.C. Wainwright	Buy
2020-11-10	Reiterato	H.C. Wainwright	Buy
2020-06-30	Iniziato	Evercore ISI	Outperform
2020-06-15	Iniziato	H.C. Wainwright	Buy
2020-04-23	Aggiornamento	Citigroup	Neutral → Buy
2019-11-08	Downgrade	JP Morgan	Overweight → Neutral
2019-09-27	Downgrade	Goldman	Neutral → Sell
2019-09-16	Downgrade	Jefferies	Buy → Hold
2019-06-04	Aggiornamento	Citigroup	Sell → Neutral
2019-05-30	Iniziato	ROTH Capital	Buy
2019-05-23	Iniziato	Stifel	Buy
2019-01-23	Iniziato	Mizuho	Buy
2018-04-10	Iniziato	JP Morgan	Overweight
2018-03-16	Iniziato	Guggenheim	Neutral
2018-03-05	Reiterato	Jefferies	Buy
2018-02-28	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2018-02-15	Downgrade	Citigroup	Neutral → Sell
2018-01-03	Aggiornamento	Citigroup	Sell → Neutral
2017-10-06	Ripresa	Goldman	Neutral

Mostra tutto

Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie

Apr 25, 2026

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionATRA - Scott Coop

Apr 25, 2026

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with ... - Bluefield Daily Telegraph

Apr 25, 2026

ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionATRA - ACCESS Newswire

Apr 25, 2026

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, I - GuruFocus

Apr 25, 2026

Apr 24, 2026

Atara Biotherapeutics (NASDAQ: ATRA) sets 2026 virtual meeting and equity plan vote - Stock Titan

Apr 24, 2026